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Abstract
Lipid-lowering drugs are used for the prevention of cardiovascular diseases. Statins are the most commonly used lipid-
lowering drugs. Evidence from preclinical and observational studies suggests that statins might improve the prognosis of
breast cancer patients. We analyzed data from the German MARIEplus study, a large prospective population-based cohort of
patients aged 50 and older, who were diagnosed with breast cancer between 2001 and 2005. For overall mortality, breast-
cancer specific mortality, and non-breast-cancer mortality, we included 3189 patients with invasive breast cancer stage I–IV,
and for recurrence risk 3024 patients with breast cancer stage I–III. We used Cox proportional hazards models to assess the
association with self-reported lipid-lowering drug use at recruitment. We stratified by study region, tumor grade, and
estrogen/progesterone receptor status, and adjusted for age, tumor size, nodal status, metastases (stage I–IV only),
menopausal hormone treatment, mode of detection, radiotherapy, and smoking. Mortality analyses were additionally
adjusted for cardiovascular disease, diabetes mellitus and body-mass index. During a median follow-up of 5.3 years, 404 of
3189 stage I–IV patients died, and 286 deaths were attributed to breast cancer. Self-reported use of lipid-lowering drugs was
non-significantly associated with increased non-breast cancer mortality (Hazard ratio (HR) 1.49, 95% confidence interval (CI)
0.88–2.52) and increased overall mortality (HR 1.21, 95% CI 0.87–1.69) whereas no association with breast cancer-specific
mortality was found (HR 1.04, 0.67–1.60). Restricted to stage I–III breast cancer patients, 387 recurrences occurred during a
median follow-up of 5.4 years. We found lipid-lowering drug use to be non-significantly associated with a reduced risk of
recurrence (HR 0.83, 95% CI 0.54–1.24) and of breast cancer-specific mortality (HR 0.89, 95% CI 0.52–1.49). Although
compatible with previous findings of an improved prognosis associated with statin use, our results do not provide clear
supportive evidence for an association with lipid-lowering drug use due to imprecise estimates.
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Introduction
Lipid-lowering drugs are used for the prevention of cardiovas-
cular diseases. Statins are the most frequently prescribed lipid-
lowering drugs, accounting for 89% of all lipid-lowering drug
prescriptions in Germany [1]. Primarily, statins inhibit HMG-CoA
reductase, the key enzyme of intracellular cholesterol synthesis,
resulting in decreasing blood lipid levels. Evidence from preclinical
research indicates that statins might have anticancerogenic
properties by inducing apoptosis and by reducing tumor growth,
angiogenesis, and metastasis [2–5]. Observational studies consis-
tently show no evidence for an influence of statins on breast cancer
risk [6]. Thus far, four studies reported on the effects of statin
intake on the prognosis of breast cancer [7–10]: One recent study
reported a reduced breast-cancer-specific mortality. Two studies
showed a statistically significant reduced risk of breast recurrence
[7,8], and one study reported a non-significant reduced risk [9].
Here, we assessed the effect of self-reported use of lipid-lowering
drugs at recruitment on risk of recurrence as well as of mortality in
a large cohort of breast cancer patients of the German
MARIEplus study.
Patients and Methods
Ethics statement. The study was approved by the ethics
committees of the University of Heidelberg and of the Hamburg
Medical Council, and the Medical Board of the State of
Rheinland-Pfalz. It was conducted in accordance with the
Declaration of Helsinki, and all study participants gave written
informed consent.
Study population. Our study population consisted of
participants of the MARIEplus study, a cohort of breast cancer
patients recruited from the MARIE study, a population-based
case-control study of breast cancer risk [11]. The cohort
consisted of patients aged between 50 and 74 years at diagnosis,
who were diagnosed with histologically confirmed in situ or
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invasive breast cancer. Patients were diagnosed with breast
cancer between January 2001 and September 2005 in the
region of Hamburg, and between August 2002 and July 2005 in
the Rhein-Neckar-Karlsruhe region.
A total of 3813 patients participated and provided relevant data.
After excluding patients with in-situ-tumors (n = 231) or previous
other tumors (n = 231), those with missing information on tumor
stage (n = 2), previous tumors (n = 10) or lipid-lowering drug intake
(n = 3) and those who had received neo-adjuvant chemotherapy
(n = 147), 3189 patients were available for mortality analyses. For
analysis of recurrence, we further excluded patients diagnosed with
tumor stage IV (n= 88) and patients with missing information on
recurrence (n = 77), resulting in 3024 patients with breast cancer
stages I – III available for analysis. To assess our results in a more
homogeneous group, we repeated all analyses restricted to
postmenopausal women diagnosed with breast cancer stages I –
III (n = 2755) as sensitivity analysis.
Data collection. Clinical and pathological characteristics of
the tumors were abstracted from hospital and pathology records.
All patients were interviewed at recruitment (2002–2005) by
trained personnel to obtain information on socio-demographic
factors, anthropometric measures, medication, menopausal hor-
mone treatment (MHT) exposure, and other established and
potential risk factors for breast cancer. Regarding the use of
medication, patients were asked if they ever took lipid-lowering
drugs on a regular basis, i.e. at least for one year. If yes, patients
were asked if they were still taking lipid-lowering drugs. We
dichotomized the information as current exposure to lipid-
lowering drugs at time of recruitment and never/past exposure
as reference category.
Outcome assessment. Vital status of participants was
determined through population registries up to the end of 2009
(100% completeness vital status follow-up), and all deaths were
verified by death certificates. Information on recurrences or
second cancers was collected via telephone interviews conducted
between May and September 2009. In addition, information was
extracted from clinical records or requested from treating
physicians to verify self-reported events (.90% of self-reported
events verified) or to obtain corresponding information on
deceased patients or patients who did not participate in the
interview (98% completeness of recurrence follow-up). Participant
information was censored at date of the event of interest, last
contact or 31 December 2009, whichever came first.
Statistical analyses. We used Cox proportional-hazards
models to analyze the association of self-reported intake of lipid-
lowering drugs at recruitment with overall mortality, breast
cancer-specific mortality, mortality from causes other than breast
cancer, and recurrence (ipsilateral/contralateral/local/regional
invasive recurrence, distant recurrence). To account for competing
risks, deaths other than the respective event of interest have been
censored in the analysis of the outcomes breast-cancer mortality,
mortality from other causes, and recurrence. We applied left
truncation to account for possible survival bias due to a time lag
between diagnosis and interview of patients [12].
All models are stratified by study region and adjusted for age at
recruitment (continuous). For the adjusted models, we included the
following prognostic variables based on prior knowledge: Tumor
size (,=2 cm, .2–,=5 cm, .5 cm, growth into chest wall/
skin), nodal status (number of affected lymph nodes: 0, 1–3, 4–9,
.=10), metastases (dichotomized, included only in mortality
analyses of stage I–IV patients). Checking the proportional
hazards assumption resulted in strong evidence for a time-
dependent effect of grade (low, moderate, high) and estrogen/
progesterone receptor status (ER+PR+, ER+PR2/ER2PR+,
ER2PR2), we therefore stratified the analyses by grade and
receptor status [13]. In the analyses of the mortality outcomes, we
additionally included the covariates cardiovascular disease, diabe-
tes mellitus and BMI, because they are indications for the
prescription of lipid-lowering drugs and therefore strongly related
to both exposure and outcome. Additional potential confounding
variables for which established prior knowledge is limited or
lacking were evaluated in the overall mortality analyses via
backward elimination and retained in all models if p,0.05. The
following four variables were included: menopausal hormone
treatment (MHT) at diagnosis (yes, no), mode of detection (self-
discovered, by physician), radiotherapy (yes, no), smoking status
(never, former, current). The following variables were not
retained: HER2 status (HER2+, HER22), type of surgery (ablatio,
breast conserving), chemotherapy (yes, no), alcohol consumption
(no alcohol consumption, ,19 g/day, .=19 g/day), body mass
index (BMI) (18.5–,25 kg/m2, ,18.5 kg/m2, 25–,30 kg/m2,
.=30 kg/m2), diabetes mellitus (yes, no), cardiovascular disease
(yes, no), occupational status (low, medium, high), formal
education (low, medium, high), leisure time physical activity since
age 50 (,28 metabolic equivalent hours (METh) per week,.=28
METh/week).
Analyses were performed using the procedures PROC FREQ,
PROC MEANS, and PROC PHREG of SAS 9.2 (SAS Institute,
Cary, NC, USA), and all statistical tests were two-sided (a = 0.05).
Results
We included 3189 stage I–IV breast cancer patients in the
mortality analyses and 3024 stage I–III patients in the recurrence
analyses. Table 1 and Table 2 show the characteristics of both
groups according to lipid-lowering drug use. The prevalence of
lipid-lowering drug use is nearly ten percent. Lipid-lowering drug
users tended to be older than non-users and had a higher
prevalence of cardiovascular disease and diabetes mellitus. The
proportion of postmenopausal women and overweight women was
somewhat higher, but the prevalence of MHT was lower. Lipid-
lowering drug users had a lower occupational status and a lower
formal education. Tumor characteristics were similar in the two
groups, with the exception of nodal status. The proportion of
tumors with affected lymph nodes was lower among lipid-lowering
drug users. Lipid-lowering drug users were less likely to have
received chemotherapy.
During a median follow-up of 5.3 years, 404 of 3189 stage I–IV
patients died, and 286 deaths were attributed to breast cancer
(Table 3). The proportion of deaths among lipid-lowering drug
users was higher than among non-users (16.1% vs. 12.3%), and the
difference was more apparent for non-breast cancer mortality
(6.6% vs. 3.4%) than for breast cancer-specific mortality (9.5% vs.
8.9%). Among 3024 stage I–III patients, 387 recurrences occurred
during a median follow-up of 5.4 years, with only a small
difference between lipid-lowering drug users and non-users (11.9%
vs. 12.9%).
Use of lipid-lowering drugs was associated with not statistically
significant increased non-breast cancer mortality (HR 1.49, 95%
CI 0.88–2.52) as well as overall mortality (HR 1.21, 95% CI 0.87–
1.69) in adjusted models (Table 4). There was no association with
breast cancer-specific mortality (HR 1.04, 95% CI 0.67–1.60).
When restricting the analyses to stage I–III patients, the
associations of overall mortality and non-breast cancer mortality
were essentially unchanged (HR 1.14, 95% CI 0.78–1.66; HR
1.44, 95% CI 0.84–2.46). Use of lipid-lowering drugs was
associated with a non-significantly reduced risk of recurrence
(HR 0.83, 95% CI 0.54–1.24) as well as of breast-cancer specific
Lipid-Lowering Drugs and Breast Cancer Prognosis
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mortality (HR 0.89, 95% CI 0.52–1.49). Restricting the analyses
to postmenopausal patients did not alter the estimates substan-
tially.
Discussion
Using data from a cohort of breast cancer patients, we were not
able to clearly confirm previous findings indicating an association
Table 1. Baseline demographic and health-related behavior characteristics of breast cancer patients by lipid-lowering drug use at
recruitment.
Characteristics stage I–IV (n=3189) stage I–III (n = 3024)
lipid-lowering
drug use
no lipid-lowering
drug use
lipid-lowering
drug use
no lipid-lowering
drug use
Patients, n (%) 305 (9.6) 2884 (90.4) 287 (9.5) 2737 (90.5)
Study region Hamburg 166 (9.4) 1610 (90.7) 156 (9.3) 1517 (90.7)
Rhein-Neckar-Karlsruhe 139 (9.8) 1274 (90.2) 131 (9.7) 1220 (90.3)
Age at diagnosis, years 50–54 17 (5.6) 431 (14.9) 16 (5.6) 416 (15.2)
55–59 33 (10.8) 654 (22.7) 30 (10.5) 614 (22.4)
60–64 85 (27.9) 839 (29.1) 81 (28.2) 805 (29.4)
65–69 113 (37.1) 670 (23.2) 107 (37.3) 631 (23.1)
.=70 57 (18.7) 290 (10.1) 53 (18.5) 271 (9.9)
menopausal status peri 10 (3.3) 269 (9.3) 10 (3.5) 259 (9.5)
post 295 (96.7) 2615 (90.7) 277 (96.5) 2478 (90.5)
Menopausal hormone
treatment at recruitment
No 186 (61.0) 1506 (52.2) 173 (60.3) 1416 (51.7)
Yes 116 (38.0) 1357 (47.1) 112 (39.0) 1302 (47.6)
Missing 3 (1.0) 21 (0.7) 2 (0.7) 19 (0.7)
BMI 18.5–,25 kg/m2 217 (71.2) 2133 (74.0) 208 (72.5) 2040 (74.5)
,18.5 kg/m2 7 (2.3) 84 (2.9) 7 (2.4) 83 (3.0)
25–,30 kg/m2 72 (23.6) 574 (19.9) 65 (22.7) 531 (19.40)
.=30 kg/m2 9 (3.0) 93 (3.2) 7 (2.4) 83 (3.03)
Smoking status Never 168 (55.1) 1506 (52.2) 157 (54.7) 1427 (52.1)
Former 85 (27.9) 793 (27.5) 82 (28.6) 765 (28.0)
Current 52 (17.1) 585 (20.3) 48 (16.7) 545 (19.9)
Alcohol consumption No alcohol consumption 50 (16.4) 406 (14.1) 48 (16.7) 373 (13.6)
,19 g/day 220 (72.1) 2082 (72.2) 206 (71.8) 1985 (72.5)
.=19 g/day 34 (11.2) 392 (13.6) 32 (11.2) 375 (13.7)
Missing 1 (0.3) 4 (0.1) 1 (0.4) 4 (0.2)
Diabetes mellitus No 235 (77.1) 2671 (92.6) 225 (78.4) 2534 (92.6)
Yes 69 (22.6) 208 (7.2) 61 (21.3) 200 (7.3)
Missing 1 (0.3) 5 (0.2) 1 (0.4) 3 (0.1)
Cardiovascular disease No 78 (25.6) 1512 (52.4) 76 (26.5) 1450 (53.0)
Yes 227 (74.4) 1372 (47.6) 211 (73.5) 1287 (47.0)
Occupation Low 131 (43.0) 1022 (35.4) 122 (42.5) 964 (35.2)
Medium 122 (40.0) 1121 (38.9) 116 (40.4) 1056 (38.6)
High 50 (16.4) 729 (25.3) 47 (16.4) 706 (25.8)
Missing 2 (0.7) 12 (0.4) 2 (0.7) 11 (0.4)
Education Low 213 (69.8) 1644 (57.0) 201 (70.0) 1549 (56.6)
Medium 59 (19.3) 806 (28.0) 53 (18.5) 771 (28.2)
High 33 (10.8) 433 (15.0) 33 (11.5) 416 (15.2)
Missing 0 1 (0.1) 0 1 (0.1)
Leisure time physical activity
since age 50
,28 METh/week 79 (25.9) 779 (27.0) 73 (25.4) 737 (26.9)
.=28 METh/week 217 (71.2) 2070 (71.8) 205 (71.4) 1968 (71.9)
Missing 9 (3.0) 35 (1.2) 9 (3.1) 32 (1.2)
doi:10.1371/journal.pone.0075088.t001
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Table 2. Baseline tumor and treatment characteristics of breast cancer patients by lipid-lowering drug use at recruitment.
Characteristics stage I–IV (n=3189) stage I–III (n = 3024)
lipid-lowering
drug use
no lipid-lowering
drug use
lipid-lowering
drug use
no lipid-lowering
drug use
Patients, n (%) 305 (9.6) 2884 (90.4) 287 (9.5) 2737 (90.5)
Stage I 140 (45.9) 1311 (45.5) 138 (48.1) 1275 (46.6)
II 121 (39.7) 1181 (41.0) 117 (40.8) 1149 (42.0)
III 32 (10.5) 316 (11.0) 32 (11.2) 313 (11.4)
IV 12 (3.9) 76 (2.6) 0 0
Histological grade Low 53 (17.4) 574 (19.9) 50 (17.4) 548 (20.0)
Moderate 166 (54.4) 1526 (52.9) 158 (55.1) 1451 (53.0)
High 84 (27.5) 771 (26.7) 77 (26.8) 725 (26.5)
Missing 2 (0.7) 13 (0.5) 2 (0.7) 13 (0.5)
Tumor size ,=2 cm 167 (54.8) 1655 (57.4) 161 (56.1) 1602 (58.5)
.2–,=5 cm 115 (37.7) 1041 (36.1) 105 (36.6) 979 (35.8)
.5 cm 14 (4.6) 105 (3.6) 14 (4.9) 92 (3.4)
Growth into chest wall/skin 9 (3.0) 78 (2.7) 7 (2.4) 61 (2.2)
Missing 0 5 (0.2) 0 3 (0.1)
Nodal status, affected
lymph nodes
0 216 (70.8) 1904 (66.0) 209 (72.8) 1834 (67.0)
1–3 59 (19.3) 707 (24.5) 54 (18.8) 668 (24.4)
4–9 21 (6.9) 162 (5.6) 18 (6.3) 149 (5.4)
.=10 9 (3.0) 107 (3.7) 6 (2.1) 86 (3.2)
Missing 0 (0.0) 4 (0.1) 0 0
Metastases at recruitment No metastases 293 (96.1) 2808 (97.4) 287 (100.0) 2737 (100.0)
Metastases 12 (3.9) 76 (2.6) 0 0
ER/PR status ER+PR+ 193 (63.3) 1857 (64.4) 182 (63.4) 1765 (64.5)
ER+PR2/ER2PR+ 61 (20.0) 539 (18.7) 57 (19.9) 505 (18.5)
ER2PR2 50 (16.4) 488 (16.9) 47 (16.4) 467 (17.1)
Missing 1 (0.3) 0 1 (0.4) 0
HER2 status HER2+ 54 (17.7) 520 (18.0) 48 (16.7) 489 (17.9)
HER22 219 (71.8) 2099 (72.8) 207 (72.1) 1991 (72.7)
Missing 32 (10.5) 265 (9.2) 32 (11.2) 257 (9.4)
Type of surgery Ablatio 81 (26.6) 850 (29.5) 75 (26.1) 776 (28.4)
Breast conserving 222 (72.8) 2018 (70.0) 210 (73.2) 1946 (71.1)
Missing 2 (0.7) 16 (0.6) 2 (0.7) 15 (0.6)
Chemotherapy No 173 (56.7) 1377 (47.8) 163 (56.8) 1310 (47.9)
Yes 127 (41.6) 1457 (50.5) 121 (42.2) 1386 (50.6)
Missing 5 (1.6) 50 (1.7) 3 (1.1) 41 (1.5)
Radiotherapy No 54 (17.7) 572 (19.8) 44 (15.3) 499 (18.2)
Yes 245 (80.3) 2276 (78.9) 237 (82.6) 2207 (80.6)
Missing 6 (2.0) 36 (1.3) 6 (2.1) 31 (1.1)
Endocrine therapy No tamoxifen and aromatase
inhibitor use
54 (17.7) 454 (15.7) 53 (18.5) 442 (16.2)
Ever tamoxifen or aromatase
inhibitor use
239 (78.4) 2270 (78.7) 225 (78.4) 2150 (78.6)
Missing 12 (3.9) 160 (5.6) 9 (3.1) 145 (5.3)
Mode of detection self-discovered (palpation,
secretion, doctor visit
because of pain)
161 (52.8) 1572 (54.5) 149 (51.9) 1477 (54.0)
discovered by routine
investigation, mammography,
ultrasound
142 (46.6) 1303 (45.2) 136 (47.4) 1252 (45.7)
Missing 2 (0.7) 9 (0.3) 2 (0.7) 8 (0.3)
doi:10.1371/journal.pone.0075088.t002
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of statin use with reduced risk of recurrence in breast cancer
patients [14] and reduced breast-cancer-specific mortality [10].
Although we observed a non-significantly reduced risk of
recurrence and of breast cancer-specific mortality in stage I–III
breast cancer patients, our estimates of association have broad
confidence intervals. This lack of precision could be due to the
comparatively small number of users of lipid-lowering drugs, and
due to a certain degree of misclassification of exposure, which is a
main limitation of our study. Information on use of lipid-lowering
drugs in general was collected in a baseline questionnaire, based
on self-reported use without validation through prescription
records. In addition, we did not have information on the precise
type and dosage of lipid-lowering drugs. Statins are the most
frequently prescribed lipid-lowering drugs (89% in Germany
2009), therefore lipid-lowering drugs could be used as a proxy for
statins [1]. This assumption is supported by follow-up information
from a subset of 2542 patients, providing medication use in more
detail, which showed that 85% of follow-up participants taking
lipid-lowering drugs actually take statins. Since statins are not sold
over-the-counter but have to be prescribed by a physician for the
secondary prevention of cardiovascular diseases, and are known to
be usually well tolerated, it is likely that the prescription is
continued after diagnosis and treatment of breast cancer.
Therefore, it seems to be reasonable to use current use at
diagnosis as a proxy for use after diagnosis. On the other hand, a
recent study showed that the proportion of adherent statin users
dropped from 64% in the year before breast cancer diagnosis to
50% during the treatment period and stayed low the subsequent
three years [15]. If the adherence would also have dropped in our
study, this would have led to an overestimation of the exposure.
The direction of the potential bias is difficult to estimate, since we
do not know if adherence is related to outcome-related variables
like severity of disease.
All three previously published studies on statins and breast
cancer recurrence used information on statin use after diagnosis.
The reported prevalence of statin use waus between 21% and 25%
[8–10]. The prevalence in our study was 10%, which was clearly
lower. All three studies included premenopausal as well as
postmenopausal patients. Kwan et al. reported a non-significant
decreased risk of recurrence associated with statin use in their US
Table 3. Follow-up time and events of breast cancer patients by lipid-lowering drug use at recruitment.
Outcomes assessed stage I–IV (n =3189) stage I–III (n =3024)
lipid-lowering
drug use
no lipid-lowering
drug use
lipid-lowering
drug use
no lipid-lowering
drug use
n patients (%) 305 (9.6) 2884 (90.4) 287 (9.5) 2737 (90.5)
Overall mortality: n events (%) 49 (16.1) 355 (12.3) 39 (13.6) 298 (10.9)
Breast cancer-specific mortality: n events (%) 29 (9.5) 257 (8.9) 20 (7.0) 201 (7.3)
Non-breast cancer mortality: n events (%) 20 (6.6) 98 (3.4) 19 (6.6) 97 (3.5)
Follow-up time for mortality: person years (median) 1552 (5.1) 15411 (5.3) 1491 (5.2) 14748 (5.4)
Recurrence: n events (%) – – 34 (11.9) 353 (12.9)
Follow-up time for recurrence: person years (median) – – 1412 (5.2) 14028 (5.5)
doi:10.1371/journal.pone.0075088.t003
Table 4. Hazard ratios for mortality and recurrence associated with lipid-lowering drug use at recruitment, compared to past or
never use.
crude* adjusted**
Patients Outcome n HR (95% CI) n HR (95% CI)
stage I–IV Overall mortality 3189 1.25 (0.93–1.70) 3085 1.21 (0.87–1.69)
Breast cancer-specific mortality 3189 1.08 (0.73–1.59) 3085 1.04 (0.67–1.60)
Non-breast cancer mortality 3189 1.66 (1.02–2.69) 3085 1.49 (0.88–2.52)
stage I–III Overall mortality 3024 1.18 (0.85–1.66) 2936 1.12 (0.77–1.62)
Breast cancer-specific mortality 3024 0.96 (0.60–1.53) 2936 0.89 (0.52–1.49)
Non-breast cancer mortality 3024 1.58 (0.96–2.59) 2936 1.43 (0.84–2.44)
Recurrence 2996 0.91 (0.63–1.32) 2912 0.83 (0.54–1.24)
stage I–III, only postmenopausal Overall mortality 2755 1.15 (0.81–1.62) 2671 1.14 (0.78–1.66)
Breast cancer-specific mortality 2755 0.89 (0.55–1.45) 2671 0.93 (0.54–1.60)
Non-breast cancer mortality 2755 1.60 (0.97–2.63) 2671 1.44 (0.84–2.46)
Recurrence 2729 0.88 (0.60–1.28) 2649 0.84 (0.57–1.26)
*stratified by region, adjusted for age.
**stratified by region, tumor grade, estrogen/progesterone receptor status; adjusted for age, the traditional prognostic factors tumor size, nodal status, (metastases,
stage I–IV only), and for the following additional covariates evaluated using backward elimination: menopausal hormone treatment at recruitment, mode of detection,
radiotherapy, and smoking. Mortality analyses are additionally adjusted for cardiovascular disease, diabetes mellitus, and body-mass index.
doi:10.1371/journal.pone.0075088.t004
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cohort of nearly 2000 early stage breast cancer patients (HR 0.67,
95% CI 0.39–1.13) [9]. Chae et al. found evidence for reduced
disease-free mortality (HR 0.40, 95% CI 0.24–0.67) associated
with post-diagnostic statin use in a US cohort of 700 breast cancer
patients diagnosed with stage II/III. Ahern et al. analyzed data
from more than 18000 stage I–III breast cancer patients from
Denmark, and found a beneficial effect of statin use on 5-year and
10-year-recurrence risk (HR 0.83, 95% CI 0.70–0.98) [7]. The
effect was even stronger when restricting the analyses to lipophilic
statins and to the lipophilic substance simvastatin. In both the
Danish study and our study population, simvastatin was the most
frequently used substance of all statins (71% and 87%, respec-
tively).
Three published studies also focused their analyses on
recurrence, most likely due to confounding issues with co-
morbidities like cardiovascular disease, diabetes mellitus and
obesity, which are strongly related to both exposure of interest
and outcome. Chae et al. included overall survival as a secondary
endpoint and reported no benefit (median survival 116 vs. 99
months, log-rank test p = 0.30) [8]. Our data suggest an increased
overall mortality associated with use of lipid-lowering drugs due to
non-breast cancer mortality. The results were not statistically
significant and may be subject to residual confounding. Nielsen
et al. assessed overall and cancer-related mortality in a cohort
comprising all Danish cancer patients diagnosed between 1995
and 2007. For the subgroup of 46562 breast cancer patients, they
reported a reduced breast-cancer specific mortality associated with
statin use (HR 0.87, 95% CI 0.79–0.99) [10]. In stage I–III
patients, our point estimate suggests a potential beneficial effect for
breast cancer-specific mortality, which is comparable with the
results of Nielsen et al. Since we censored events other than the
event of interest in the analysis, it is unlikely that our results for
breast cancer-specific mortality and for recurrence are severely
biased by the influence of competing risks. We also have to take
into account the possibility that not lipid-lowering drugs but other
patient characteristics associated with the medication could be the
underlying cause for the observed associations. Increased levels of
cholesterol might be associated with a reduced risk of metastases
[16]. On the other hand, there is evidence that increased BMI is
associated with a poorer prognosis after breast cancer diagnosis
[17,18]. Hypercholesterolemia and increased BMI are indications
for lipid-lowering drugs, and even though we adjusted for BMI,
this might not be sufficient to rule out the possibility of
confounding by indication [19].
The strengths of our analyses include the use of data from a
study with comprehensive information on patient and tumor
characteristics and on recurrence and mortality events. The
available information allowed us to adjust for established
prognostic factors. One could argue that using self-reported
medication usage instead of prescription records could also be
regarded as an advantage: Given the known gap between
prescription and actual intake of medication, especially of statins
in an elderly population, self-reported use might be more realistic
than prescriptions [20,21].
Although our results are compatible with previous findings of a
beneficial effect of statins on breast cancer prognosis, they do not
provide clear supportive evidence for an association with lipid-
lowering drug use due to imprecise estimates.
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